Johnson & Johnson/Omrix File Evicel sBLA For General Hemostasis In Surgery
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-bleeding product’s human serum-derived Thrombin component has a September stand-alone user fee date, Omrix tells “The Pink Sheet” DAILY.
You may also be interested in...
Johnson & Johnson/Omrix’s Evicel Approved For Use In Vascular Surgery
Partners anticipate first-quarter 2008 approval of liquid fibrin sealant for general hemostasis in surgery.
Johnson & Johnson/Omrix’s Evicel Approved For Use In Vascular Surgery
Partners anticipate first-quarter 2008 approval of liquid fibrin sealant for general hemostasis in surgery.
ZymoGenetics Sees Faster Approval Of Second rhThrombin Configuration
FDA’s decision to not require Phase III study for spray version could shave 18 months off of development.